News

A treatment course of low-dose rituximab eased measures of clinical severity, improved quality of life, and allowed lower steroid doses to be used in myasthenia gravis (MG) patients who have antibodies against muscle-specific tyrosine kinase (MuSK). That’s according to a small study in China that looked at a…

Myasthenia gravis (MG) patients on long-term treatment with intravenous immunoglobulin (IVIg) or nonsteroidal immunosuppressants have significantly higher rates of disease crises and exacerbations, and subsequent greater healthcare costs, according to a retrospective analysis of insurance claims from a U.S. database. Overall, these findings highlight that treatments capable of…

Vyvgart (efgartigimod alfa) has been listed on China’s 2023 National Reimbursement Drug List (NRDL) as a treatment for adults with generalized myasthenia gravis (gMG) who test positive for self-reactive antibodies against the acetylcholine receptor (AChR) protein. Issued each year by China’s National Healthcare Security Administration (NHSA), the NRDL…

KYV-101, an experimental cell therapy for myasthenia gravis (MG) in development by Kyverna Therapeutics, has been granted fast track status by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to therapies that have the potential to improve care for serious illnesses. The designation is…

A new generic formulation of pyridostigmine bromide — a muscle-strengthening medication sold under the brand name Mestinon — is now available for people with myasthenia gravis (MG) in the U.S. This generic, which like the name-brand therapy is available as an oral syrup at a dose strength of…

Vyvgart (efgartigimod) generally is safe and leads to both significant symptom reductions and improvements in function in people with hard-to-treat generalized myasthenia gravis (gMG), according to a real-world, single-center study in the U.S. These results, the researchers say, “[provide] further support for the use of [Vyvgart] in clinical…

Myasthenia gravis (MG) caused by the presence of self-reactive antibodies targeting muscle-specific kinase (MuSK) affects mostly women in Japan, leading to generalized muscle weakness, particularly in the face and neck, a study reports. About half of 50 study patients had refractory MG, meaning they failed to respond to standard…

Treatment with intravenous immunoglobulin (IVIG) during pregnancy may have helped ease symptoms of a fetal disorder in a girl born to a mother with myasthenia gravis (MG), according to a report from Germany. The woman’s firstborn had developed severe FARAD (or fetal acetylcholine receptor antibody-related disorder), which occurs…

Among people with myasthenia gravis (MG) living in Australia, women and seronegative patients — those whose tests fail to show MG-associated antibodies — reported a significantly higher disease toll in an online survey. This toll included a greater range of disease symptoms, earlier disease onset, longer waits…

Kyverna Therapeutics’ investigational cell therapy KYV-101 safely and effectively improved muscle strength and reduced fatigue in a woman with severe, hard-to-treat generalized myasthenia gravis (gMG), according to a case report. The patient was treated based on an individual case evaluation and outside of a clinical trial. “This groundbreaking…